Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 7Phase 1/2 3Phase 1 3Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Cisplatin 12Magnetic Resonance Spectroscopy 10Specimen Handling 9Gemcitabine 9Carboplatin 9pembrolizumab 8Pemetrexed 8atezolizumab 7Radiotherapy, Intensity-Modulated 5Platinum 5Paclitaxel 5Nivolumab 5Immunoglobulin G 5Doxorubicin 5Docetaxel 5Disulfides 5Bevacizumab 5130-nm albumin-bound paclitaxel 51,2-diaminocyclohexaneplatinum II citrate 5Cetuximab 4Biopsy 4Temozolomide 3Rituximab 3Dexamethasone 3(225)Ac-DOTA-c(RGDyK) 3venetoclax 2pegfilgrastim 2merphos 2liposomal doxorubicin 2durvalumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × daratumumab × 30 days × Clear all
NCT07095452 2026-06-02

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

AbbVie

Phase 2/3 Recruiting
660 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡